论文部分内容阅读
目的观察顺铂作为辅助用药治疗晚期胃癌的应用效果。方法选取医院收治的晚期胃癌患者48例作为研究对象,随机分为观察组和对照组,每组24例。对照组采用常规的多西他赛联合氟尿嘧啶方案进行化疗,观察组在此基础上,增加辅助应用顺铂,每3周为1个疗程,持续治疗4个疗程。结果观察组患者病情控制率为91.7%,高于对照组的66.7%(P<0.05);2组患者总不良反应发生率、半年生存率比较差异均无统计学意义(P>0.05)。观察组患者1年生存率(75.0%)、2年生存率(54.2%)均高于对照组(45.8%)、(25.0%),差异有统计学意义(P<0.05)。结论顺铂作为辅助用药可有效提高晚期胃癌的近期疗效与远期生存率,并不增加不良反应发生风险,安全性高,值得广泛推广应用。
Objective To observe the effect of cisplatin as adjuvant therapy in the treatment of advanced gastric cancer. Methods Forty-eight patients with advanced gastric cancer admitted to the hospital were selected as study subjects and randomly divided into observation group and control group, with 24 cases in each group. The control group received conventional docetaxel and fluorouracil regimen for chemotherapy. On the basis of this, the observation group added adjuvant cisplatin once every 3 weeks for 4 courses. Results The rate of disease control in observation group was 91.7%, which was higher than that in control group (66.7%, P <0.05). There was no significant difference in adverse reaction rate and half-year survival rate between two groups (P> 0.05). The 1-year survival rate (75.0%) and 2-year survival rate (54.2%) in the observation group were significantly higher than those in the control group (45.8% and 25.0%, respectively) (P 0. 05). Conclusion Cisplatin as adjuvant therapy can effectively improve the short-term efficacy and long-term survival rate of advanced gastric cancer. It does not increase the risk of adverse reactions, and is safe and should be widely applied.